Abstract
The term idiopathic or lone atrial fibrillation (AF) is commonly used in the young and apparently healthy individual who suffers from AF. Although there is conflicting evidence concerning prognosis, these patients are at risk to develop (vascular) comorbidities in the years following AF onset. It is conceivable that early stages of vascular disease, undetectable by the routine diagnostics, may contribute to the pathophysiology of “apparently” idiopathic AF.
At present, more advanced diagnostics have become available that can be deployed at low threshold in order to detect early stage or yet subclinical cardiovascular disease. In this respect one could raise the question whether idiopathic AF exists at all or that the arrhythmia acts as a harbinger of as yet undetected underlying vascular disease in this specific population. Assuming that idiopathic AF is the final arrhythmic expression of underlying genetic mutations and/or vascular diseases, high priority should be given to trace identifiable predisposing factors or the presence of early stages of underlying disease in order to treat these, or prevent their complications. A more comprehensive quest for potential hidden causes of idiopathic AF creates new therapeutic dilemmas, but also encourages further research regarding pathophysiology and new early treatment opportunities in patients with atrial fibrillation in general.
The present review provides more insight regarding diverse pathophysiological mechanisms in the fundamental basis for idiopathic AF, outlines prognostic and treatment implications, and questions the robustness of its definition.
Keywords: Idiopathic, lone, atrial fibrillation, cardiovascular disease, pathophysiology.
Current Pharmaceutical Design
Title:Pathophysiology of Idiopathic Atrial Fibrillation - Prognostic and Treatment Implications
Volume: 21 Issue: 5
Author(s): B. Weijs, U. Schotten and H.J.G.M. Crijns
Affiliation:
Keywords: Idiopathic, lone, atrial fibrillation, cardiovascular disease, pathophysiology.
Abstract: The term idiopathic or lone atrial fibrillation (AF) is commonly used in the young and apparently healthy individual who suffers from AF. Although there is conflicting evidence concerning prognosis, these patients are at risk to develop (vascular) comorbidities in the years following AF onset. It is conceivable that early stages of vascular disease, undetectable by the routine diagnostics, may contribute to the pathophysiology of “apparently” idiopathic AF.
At present, more advanced diagnostics have become available that can be deployed at low threshold in order to detect early stage or yet subclinical cardiovascular disease. In this respect one could raise the question whether idiopathic AF exists at all or that the arrhythmia acts as a harbinger of as yet undetected underlying vascular disease in this specific population. Assuming that idiopathic AF is the final arrhythmic expression of underlying genetic mutations and/or vascular diseases, high priority should be given to trace identifiable predisposing factors or the presence of early stages of underlying disease in order to treat these, or prevent their complications. A more comprehensive quest for potential hidden causes of idiopathic AF creates new therapeutic dilemmas, but also encourages further research regarding pathophysiology and new early treatment opportunities in patients with atrial fibrillation in general.
The present review provides more insight regarding diverse pathophysiological mechanisms in the fundamental basis for idiopathic AF, outlines prognostic and treatment implications, and questions the robustness of its definition.
Export Options
About this article
Cite this article as:
Weijs B., Schotten U. and Crijns H.J.G.M., Pathophysiology of Idiopathic Atrial Fibrillation - Prognostic and Treatment Implications, Current Pharmaceutical Design 2015; 21 (5) . https://dx.doi.org/10.2174/1381612820666140825150057
DOI https://dx.doi.org/10.2174/1381612820666140825150057 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Renin-Angiotensin System in Diabetes
Protein & Peptide Letters Regenerative Approaches to Post-Myocardial Infarction Heart Failure
Current Pharmaceutical Design Impact of N-acetylcysteine and Etodolac Treatment on Systolic and Diastolic Function in a Rat Model of Myocardial Steatosis Induced by High-Fat-Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets Vascular and Cardiac Oxidative Stress and Inflammation as Targets for Cardioprotection
Current Pharmaceutical Design Heat Shock Paradox and a New Role of Heat Shock Proteins and their Receptors as Anti-Inflammation Targets
Inflammation & Allergy - Drug Targets (Discontinued) Diabetes and Vascular Disease: Is It All About Glycemia?
Current Pharmaceutical Design Matrix Metalloproteinases as Valid Clinical Target
Current Pharmaceutical Design Differentiation of Mesenchymal Stem Cells from Humans and Animals into Insulin-producing Cells: An Overview <i>In Vitro</i> Induction Forms
Current Stem Cell Research & Therapy A Novel Long-circulating DOX Liposome: Formulation and Pharmacokinetics Studies
Pharmaceutical Nanotechnology Side Effects of AAS Abuse: An Overview
Mini-Reviews in Medicinal Chemistry Biochemical Markers of Cardiovascular Damage from Tobacco Smoke
Current Pharmaceutical Design Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Current Pharmaceutical Design Nutrition, Nitrogen Requirements, Exercise and Chemotherapy-Induced Toxicity in Cancer Patients. A puzzle of Contrasting Truths?
Anti-Cancer Agents in Medicinal Chemistry Doxorubicin Sensitizes the Non-Small Cell Lung Cancer Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated (TRAIL) Apoptosis In Vitro but not In Vivo
Letters in Drug Design & Discovery The Heart Metabolism: Pathophysiological Aspects in Ischaemia and Heart Failure
Current Pharmaceutical Design Triglyceride Level Affecting Shared Susceptibility Genes in Metabolic Syndrome and Coronary Artery Disease
Current Medicinal Chemistry Postoperative Atrial Fibrillation - What Do We Really Know?
Current Vascular Pharmacology Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets Efficacy of Enzyme Replacement Therapy in Fabry Disease
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Cardiac Applications for Human Pluripotent Stem Cells
Current Pharmaceutical Design